These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38270275)

  • 1. Down Syndrome Biobank Consortium: A perspective.
    Aldecoa I; Barroeta I; Carroll SL; Fortea J; Gilmore A; Ginsberg SD; Guzman SJ; Hamlett ED; Head E; Perez SE; Potter H; Molina-Porcel L; Raha-Chowdhury R; Wisniewski T; Yong WH; Zaman S; Ghosh S; Mufson EJ; Granholm AC
    Alzheimers Dement; 2024 Mar; 20(3):2262-2272. PubMed ID: 38270275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease and down syndrome: from meiosis to dementia.
    Petronis A
    Exp Neurol; 1999 Aug; 158(2):403-13. PubMed ID: 10415146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common genetic signatures of Alzheimer's disease in Down Syndrome.
    Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A
    F1000Res; 2020; 9():1299. PubMed ID: 33633844
    [No Abstract]   [Full Text] [Related]  

  • 4. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.
    Doran E; Keator D; Head E; Phelan MJ; Kim R; Totoiu M; Barrio JR; Small GW; Potkin SG; Lott IT
    J Alzheimers Dis; 2017; 56(2):459-470. PubMed ID: 27983553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.
    Mok KY; Jones EL; Hanney M; Harold D; Sims R; Williams J; Ballard C; Hardy J
    Neurobiol Aging; 2014 Jun; 35(6):1513.e1-5. PubMed ID: 24462566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
    Rafii MS; Zaman S; Handen BL
    J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome.
    Patel A; Rees SD; Kelly MA; Bain SC; Barnett AH; Thalitaya D; Prasher VP
    Neurosci Lett; 2011 Jan; 487(2):144-8. PubMed ID: 20946940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.
    Mumford P; Tosh J; Anderle S; Gkanatsiou Wikberg E; Lau G; Noy S; Cleverley K; Saito T; Saido TC; Yu E; Brinkmalm G; Portelius E; Blennow K; Zetterberg H; Tybulewicz V; Fisher EMC; Wiseman FK
    J Neurosci; 2022 Aug; 42(33):6453-6468. PubMed ID: 35835549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using mouse models to understand Alzheimer's disease mechanisms in the context of trisomy of chromosome 21.
    Cannavo C; Tosh J; Fisher EMC; Wiseman FK
    Prog Brain Res; 2020; 251():181-208. PubMed ID: 32057307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
    Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
    Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease and Down syndrome.
    Schweber MS
    Prog Clin Biol Res; 1989; 317():247-67. PubMed ID: 2532369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease.
    Teipel SJ; Hampel H
    Behav Genet; 2006 May; 36(3):405-15. PubMed ID: 16485178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome.
    Patel A; Rees SD; Kelly MA; Bain SC; Barnett AH; Prasher A; Arshad H; Prasher VP
    BMC Res Notes; 2014 Jan; 7():42. PubMed ID: 24438528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.
    Hamlett ED; Boger HA; Ledreux A; Kelley CM; Mufson EJ; Falangola MF; Guilfoyle DN; Nixon RA; Patterson D; Duval N; Granholm AC
    Curr Alzheimer Res; 2016; 13(1):35-52. PubMed ID: 26391050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome.
    Martins RN; Clarnette R; Fisher C; Broe GA; Brooks WS; Montgomery P; Gandy SE
    Neuroreport; 1995 Jul; 6(11):1513-6. PubMed ID: 7579137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.
    Strydom A; Coppus A; Blesa R; Danek A; Fortea J; Hardy J; Levin J; Nuebling G; Rebillat AS; Ritchie C; van Duijn C; Zaman S; Zetterberg H
    Alzheimers Dement (N Y); 2018; 4():703-713. PubMed ID: 30581976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.
    Di Domenico F; Pupo G; Tramutola A; Giorgi A; Schininà ME; Coccia R; Head E; Butterfield DA; Perluigi M
    Free Radic Biol Med; 2014 Jun; 71():270-280. PubMed ID: 24675226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.